Skip to main content
Daily Report

Daily Cosmetic Research Analysis

11/19/2025
3 papers selected
3 analyzed

A single-center randomized controlled trial showed that adding intralesional bleomycin to low-dose propranolol markedly improved regression of infantile hemangioma with comparable safety. A large retrospective cohort comparing robotic versus open thyroidectomy for differentiated thyroid cancer found better long-term recurrence-free survival, fewer complications, and superior quality-of-life and cosmetic outcomes with robotic surgery. A prospective comparative study in Thai schoolgirls documented

Summary

A single-center randomized controlled trial showed that adding intralesional bleomycin to low-dose propranolol markedly improved regression of infantile hemangioma with comparable safety. A large retrospective cohort comparing robotic versus open thyroidectomy for differentiated thyroid cancer found better long-term recurrence-free survival, fewer complications, and superior quality-of-life and cosmetic outcomes with robotic surgery. A prospective comparative study in Thai schoolgirls documented very low cure rates with over-the-counter pediculicide shampoos, supporting emerging insecticide resistance and the need for updated guidelines.

Research Themes

  • Combination therapy optimization for infantile hemangioma
  • Robotic surgery and long-term oncologic and cosmetic outcomes
  • Public health response to insecticide resistance in consumer pediculicides

Selected Articles

1. Propranolol (1 mg/kg/day) with intralesional bleomycin versus propranolol monotherapy for infantile hemangioma: a randomized controlled trial.

78Level IRCT
Frontiers in pharmacology · 2025PMID: 41256263

In 260 infants with infantile hemangioma, adding monthly intralesional bleomycin to low-dose propranolol significantly increased the 6-month excellent response rate versus propranolol alone and doubled complete regression rates. Early atrophy within 24 hours and improvements in color and volume were greater with combination therapy, with a comparable safety profile.

Impact: This randomized trial provides high-level evidence supporting a practical combination regimen that accelerates tumor regression and improves cosmetic outcomes while maintaining safety in infants.

Clinical Implications: For infants requiring systemic therapy for IH, consider adding intralesional bleomycin to low-dose propranolol to enhance early and overall responses and optimize cosmetic outcomes, with appropriate monitoring.

Key Findings

  • Excellent therapeutic response at 6 months: 77.69% (combination) vs 50.00% (monotherapy); P < 0.001
  • Complete regression: 33.07% vs 15.38%; P = 0.001
  • Greater early response with more pronounced tumor atrophy within 24 hours; P < 0.001
  • Significant improvements in color scores and tumor volume reduction from baseline (P < 0.001)
  • Comparable safety profile between groups in this trial

Methodological Strengths

  • Prospective randomized controlled design with adequate sample size (n=260)
  • Predefined primary endpoint with statistically robust differences

Limitations

  • Single-center study limits generalizability
  • Blinding and allocation concealment are not detailed; short (6-month) primary follow-up

Future Directions: Multicenter, blinded RCTs with standard-dose comparators and longer follow-up should assess durability, relapse, optimal dosing intervals, and safety, including VSS and functional outcomes.

OBJECTIVE: To evaluate the efficacy and safety of oral propranolol (1 mg/kg/day) combined with intralesional bleomycin injections versus propranolol monotherapy at the same dosage for infantile hemangioma (IH). This study investigates if a low-dose propranolol regimen can be enhanced with local therapy to improve outcomes while maintaining a favorable safety profile. METHODS: This single-center, prospective, randomized controlled trial enrolled 260 infants (aged 3-11 months, mean age 5.34 ± 2.57 months) with IH requiring systemic therapy. Participants were randomly assigned (1:1) to either the combination group (propranolol plus monthly intralesional bleomycin, n = 130) or the monotherapy group (propranolol alone, n = 130). The primary efficacy endpoint was the proportion of patients achieving an excellent therapeutic response (complete regression or marked effectiveness) at 6 months. Secondary outcomes included early therapeutic response, changes in hemangioma color score, tumor volume reduction, Vancouver Scar Scale (VSS) scores, and incidence of adverse events. RESULTS: Baseline characteristics were comparable. After 6 months, a significantly higher proportion of patients in the combination group achieved the primary endpoint (77.69% vs. 50.00%; P < 0.001). The combination group had higher rates of complete regression (33.07% vs. 15.38%, P = 0.001) and marked effectiveness (44.61% vs. 34.61%, P = 0.083). A superior early response was noted in the combination group, with a more pronounced degree of tumor atrophy within 24 h (P < 0.001). Post-treatment color scores (change from baseline, P < 0.001) and tumor volume (1.63 ± 0.70 cm CONCLUSION: In infants with IH, augmenting a low-dose oral propranolol regimen (1 mg/kg/day) with monthly intralesional bleomycin is significantly more effective than low-dose propranolol monotherapy. This combination strategy accelerates tumor regression and yields superior cosmetic outcomes, all while maintaining a comparable safety profile.

2. Long-term outcomes of robotic vs. open thyroidectomy for differentiated thyroid cancer: efficacy, safety and quality of life.

68.5Level IIICohort
International journal of surgery (London, England) · 2025PMID: 41255276

In a 6,249-patient retrospective cohort, open thyroidectomy had higher recurrence, hypoparathyroidism, and permanent hoarseness rates than robotic thyroidectomy. Robotic surgery provided better long-term recurrence-free survival after 100 months and superior patient-reported quality-of-life and scar outcomes.

Impact: This large-scale, long-term comparative analysis informs surgical decision-making by linking robotic approaches to improved oncologic control, fewer complications, and better patient-reported outcomes including cosmetic results.

Clinical Implications: For eligible differentiated thyroid cancer patients, robotic thyroidectomy may be prioritized when feasible, given lower complication rates, improved long-term RFS, and superior scar/QOL metrics; careful patient selection and surgeon expertise remain critical.

Key Findings

  • Recurrence rate: 2.29% (open) vs 1.82% (robotic); P = .02
  • Higher transient and permanent hypoparathyroidism in open surgery; P < .001
  • Higher permanent hoarseness in open surgery; P = .002
  • RFS probability declined markedly after 100 months in the open group, falling below robotic; P = .027
  • Robotic group had better SF-36 domains and SCAR-Q scores; P < .001

Methodological Strengths

  • Very large sample size with decade-long period and long-term follow-up
  • Use of validated patient-reported outcome measures (SF-36, SCAR-Q) alongside clinical endpoints

Limitations

  • Retrospective, non-randomized design with potential selection and confounding biases
  • Learning curve and surgeon/center effects not fully controlled

Future Directions: Prospective multicenter studies with risk adjustment and cost-effectiveness analyses should validate long-term oncologic, functional, and cosmetic benefits of robotic thyroidectomy across disease extents.

OBJECTIVE: To compare robotic vs. open thyroidectomy's long-term safety, efficacy, and quality of life for differentiated thyroid cancer. BACKGROUND: Early research showed that robotic thyroid surgery better preserves parathyroid glands and nerves compared to open surgery, but its long-term efficacy and safety remain uncertain. Comparative studies across various extents of thyroidectomy should be enhanced to include long-term follow-up, large sample sizes, and robust evidence from extensive clinical experience. METHODS: This retrospective cohort study included 6,249 patients who underwent open or robotic thyroidectomy in 2014-2024 at a 3:1 ratio (aged 15 to 80 years; 4,659 females and 1,590 males) from a cohort of 11,733 who underwent OT or RT were analyzed. Postoperative complications were recorded, and patients were assessed using quality of life and aesthetic outcome scales. Patients were evaluated using Short Form-36, voice/swallowing/neck impairment scales, and the SCAR-Q questionnaire. Clinical-pathological characteristics, postoperative complications, quality of life, and aesthetic outcome scores were compared. RESULTS: Compared to the robotic thyroidectomy group, the open thyroidectomy group had a higher recurrence rate [135 (2.29%) vs. 29 (1.82%); P = .02], transient and permanent hypoparathyroidism(P < .001) and permanent hoarseness rate(P = .002). The OT group showed a marked decline in RFS probability after 100 months post-surgery, falling below that of the RT group(P = .027). The open thyroidectomy group had higher swallowing and voice impairment scores than the robotic thyroidectomy group (P < .001) and performed worse in physiological function, body pain, general health, vitality, social function, mental health, health change, and SCAR-Q scores (P < .001) after surgery. CONCLUSIONS: Besides its well-recognized cosmetic benefits, robotic thyroidectomy demonstrated superior elegance, effectiveness, and safety across various surgical scopes, significantly enhancing the long-term postoperative quality of life for patients with differentiated thyroid cancer. These findings affirm RT as a valuable surgical option, particularly for those seeking enhanced cosmetic outcomes and requiring complex procedures.

3. Treatment failure of over-the-counter pediculicide shampoos in Thai schoolgirls: Evidence of insecticide resistance.

56Level IIICohort
Parasitology research · 2025PMID: 41258179

In a prospective three-arm comparison of 135 Thai schoolgirls, cure rates at day 14 were low: 42.22% for carbaryl, 24.44% for Stemona extract, and 6.67% for permethrin after two applications. Findings align with insecticide resistance trends and call for alternatives (e.g., ivermectin, abametapir, dimeticone), guideline updates, and resistance surveillance.

Impact: Provides pragmatic field evidence of poor real-world effectiveness of common OTC pediculicides, informing public health policy and consumer guidance in endemic settings.

Clinical Implications: Clinicians and schools should anticipate low cure rates with common OTC pediculicides and consider alternative agents/mechanisms, coordinated screening, simultaneous treatment, and local resistance surveillance.

Key Findings

  • Cure at day 14: carbaryl 42.22%, Stemona 24.44%, permethrin 6.67% (n=45 per group)
  • Two applications were administered on day 0 and day 7 per manufacturer instructions
  • No side effects reported; none of the shampoos achieved complete eradication
  • Outcomes were especially poor in heavy infestations
  • Findings support emerging resistance and recommend alternatives (ivermectin, abametapir, dimeticone) and updated guidelines

Methodological Strengths

  • Prospective allocation into three parallel treatment groups with equal sample sizes
  • Standardized application schedule and objective comb-based cure assessment at day 14

Limitations

  • Non-randomized design with potential selection and performance biases
  • Short follow-up and single province setting limit generalizability; resistance not genotyped

Future Directions: Randomized trials comparing alternative mechanisms (ivermectin, abametapir, dimeticone) with molecular resistance profiling and cost-effectiveness analyses in school-based programs.

The increasing resistance to chemical pediculicides has raised concerns about the efficacy of head lice treatments, including in Thailand. This study evaluated the efficacy of three commercially available pediculicide shampoos (0.75% permethrin, 0.6% carbaryl, and 0.12% Stemona root crude extract) among infested children in Chonburi Province, Thailand. A pre-test/post-test experimental design was conducted with 135 infested female children assigned to three treatment groups (n = 45 each), with no significant differences in baseline demographic characteristics (level of head lice infestations, hairstyle, and hair length). Each group received two applications (Day 0 and Day 7) of the allocated pediculicide shampoo, following the manufacturer's instructions. The final proportion of cured individuals was assessed on Day 14 after treatment using a fine-tooth comb. The observed percentages of cured individuals were 42.22% for carbaryl shampoo, 24.44% for Stemona shampoo, and 6.67% for permethrin shampoo. No side effects were reported, although none of the shampoos achieved complete eradication, with particularly poor outcomes in children with heavy infestations. These findings provide clinical evidence of reduced efficacy of over-the-counter pediculicides in Thailand, consistent with emerging resistance trends. More effective alternatives with different mechanisms of action, including ivermectin, abametapir, and dimeticone-based products, should be considered, although their current availability in Thailand remains limited. In the interim, development of locally available herbal formulations, together with school-based screening and simultaneous treatment, represents more feasible strategies. These results highlight the need for updated treatment guidelines, restriction of ineffective products, and regular resistance surveillance to ensure effective control.